Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vancomycin HCl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xellia Pharmaceuticals has received approval for 3 additional dosages of VANCO READY™, expanding its range of room-temperature-stable, ready-to-use (RTU) Vancomycin injection premix bags.
Product Name : Vanco Ready
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 09, 2020
Lead Product(s) : Vancomycin HCl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Agreement significantly expands biorphen commercial footprint and provides access to institutions that prefer ready-to-use injectable formulations.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Phenylephrine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration